Detail akcie Medigene N online

Business Summary: Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The Company operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, MediGene AG revenues decreased 81% to EUR6M. Net loss increased 94% to EUR16.2M. Revenues reflect Germany segment decrease of 76% to EUR6M. Higher net loss reflects Immunotherapy segment loss increase of 85% to EUR16.1M. Basic Earnings per Share excluding Extraordinary Items decreased from -EUR0.34 to -EUR0.66.